Education
About Us
Working with TipRanks
Follow Us
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
TRDA Stock Chart & Stats
$11.93
-$0.56(-3.25%)
At close: 4:00 PM EST
$11.93
-$0.56(-3.25%)
Day’s Range― - ―
52-Week Range$4.93 - $12.93
Previous CloseN/A
Volume35.15K
Average Volume (3M)207.61K
Market Cap
$456.73M
Enterprise Value$416.49M
Total Cash (Recent Filing)$295.70M
Total Debt (Recent Filing)$50.93M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
May 07, 2026EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding38,284,313
10 Day Avg. Volume164,988
30 Day Avg. Volume207,606
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)16.73
P/FCF Ratio-3.28
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue16.38
Enterprise Value/Gross Profit-30.12
Enterprise Value/Ebitda-2.92
Forecast
1Y Price Target
$20.00Price Target Upside67.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.11
Revenue Forecast (FY)$24.99M
Bulls Say, Bears Say
Bulls Say
Dose-escalation EfficacyAdvancement to a higher-dose cohort creates potential for a top-line readout showing meaningful increases in dystrophin that could validate the program's efficacy.
EEV Delivery TechnologyHuman target engagement and strong exon skipping in animal models indicate the endosomal escape vehicle may deliver therapies into muscle and heart cells more effectively than competing approaches.
Pipeline Expansion And Regulatory ProgressMultiple programs across muscular dystrophy and inherited retinal disease, plus regulatory authorization to start a study in the United Kingdom and an ongoing partnered program, broaden the number of potential clinical readouts and value inflection points.
Bears Say
Binary Readout Valuation RiskCompany value depends heavily on early-stage clinical readouts, so unfavorable or ambiguous trial results could sharply reduce investor confidence and share valuation.
Class Safety ConcernsSimilar exon-skipping therapies have been associated with issues such as low magnesium and kidney-related adverse events, posing a material safety risk that could affect development and uptake.
Small-cohort UncertaintyReliance on small initial cohorts leaves uncertainty about tolerability and rare adverse events, meaning larger participant groups could reveal safety signals that delay or alter development plans.
Entrada Therapeutics Inc News
TRDA FAQ
What was Entrada Therapeutics Inc’s price range in the past 12 months?
Entrada Therapeutics Inc lowest stock price was $4.93 and its highest was $12.93 in the past 12 months.
What is Entrada Therapeutics Inc’s market cap?
Entrada Therapeutics Inc’s market cap is $456.73M.
When is Entrada Therapeutics Inc’s upcoming earnings report date?
Entrada Therapeutics Inc’s upcoming earnings report date is May 07, 2026 which is in 65 days.
How were Entrada Therapeutics Inc’s earnings last quarter?
Entrada Therapeutics Inc released its earnings results on Feb 26, 2026. The company reported -$0.94 earnings per share for the quarter, beating the consensus estimate of -$1.15 by $0.21.
Is Entrada Therapeutics Inc overvalued?
According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued.
Does Entrada Therapeutics Inc pay dividends?
Entrada Therapeutics Inc does not currently pay dividends.
What is Entrada Therapeutics Inc’s EPS estimate?
Entrada Therapeutics Inc’s EPS estimate is -1.02.
How many shares outstanding does Entrada Therapeutics Inc have?
Entrada Therapeutics Inc has 38,284,313 shares outstanding.
What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?
Entrada Therapeutics Inc reported an EPS of -$0.94 in its last earnings report, beating expectations of -$1.15. Following the earnings report the stock price went up 6.761%.
Which hedge fund is a major shareholder of Entrada Therapeutics Inc?
Currently, no hedge funds are holding shares in TRDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entrada Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.00 (67.64% Upside)
$20.00 (67.64% Upside)
Blogger Sentiment
Bullish
TRDA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 250.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.1%
Last 30 Days ▼ 16.6%
Last 30 Days ▼ 16.6%
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.41%
12-Months-Change
Fundamentals
Return on Equity
-39.13%
Trailing 12-Months
Asset Growth
-28.30%
Trailing 12-Months
Company Description
Entrada Therapeutics Inc
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
TRDA Stock 12 Month Forecast
Average Price Target
$20.00
▲(67.64% Upside)
Technical Analysis
―
Black Diamond Therapeutics
―
C4 Therapeutics
―
Ventyx Biosciences
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
36.14% Insiders
8.49% Mutual Funds
0.72% Other Institutional Investors
46.46% Public Companies and
Individual Investors